“Ariosa Diagnostics is very excited to announce the official launch of the Harmony Prenatal Test and the agreement with LabCorp, which helps us deliver on the promise of bringing an affordable and accessible prenatal testing option to pregnant women and their physicians,” said Ken Song, MD, chief executive officer at Ariosa Diagnostics. “With enhanced test performance and simplicity, the Harmony Prenatal Test can be reliably incorporated into the management of pregnancies.”
The Harmony Prenatal Test, which detects common fetal trisomies such as Trisomy 21 (associated with Down syndrome), will be offered through LabCorp and will be available at its 1,000+ patient service centers. The test is performed using a simple maternal blood draw taken at a doctor’s office or patient service center, and provides the safety of screening tests with accuracy approaching that of invasive testing for common fetal trisomies. The test is available to pregnant women of at least 10 weeks gestational age with a single fetus conceived without the use of an egg donor.
"We are pleased to be able to offer this novel, non-invasive prenatal test,” indicated Mark Brecher, MD, LabCorp’s chief medical officer. “Ariosa Diagnostics’ Harmony Prenatal Test adds another option to LabCorp’s comprehensive prenatal testing menu.”
“The Harmony Prenatal Test is an affordable, high-quality test that provides a new choice for women,” said Dr. Song. “Together with LabCorp, we are committed to ensuring that the latest advances in prenatal testing are accessible to all healthcare providers and women.”